While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Moderna in a note issued to investors ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for Moderna in a research note issued to ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...

The company now expects revenue for 2025 to fall between $1.5 billion and $2.5 billion, a steep reduction from its previous ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...